Rethinking drug policies in the context of the acquired immunodeficiency syndrome. NLM AIDSLINE Important note: Information in this article was accurate in 1988. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Rethinking drug policies in the context of the acquired immunodeficiency syndrome.

Bull Narc. 1987;39(2):29-35. Unique Identifier : AIDSLINE MED/88209775
Drummond C; Edwards G; Glanz A; Glass I; Jackson P; Oppenheimer E; Sheehan M; Taylor C; Thom B; Institute of Psychiatry, Addiction Research Unit, Advisory; Council on Misuse of Drugs, United Kingdom of Great Britain.

Abstract: This article presents a policy analysis of the needed responses to the problems associated with the acquired immunodeficiency syndrome and drug misuse that are now being experienced in the United Kingdom of Great Britain and Northern Ireland. Among the issues considered is the overall organizational and administrative capacity of a country to deal with a new acute demand and the probable need for more national centralization of planning and effort in the drug field. Policies must aim at small multiple gains rather than at master-strokes. International communication must be strengthened. The human immunodeficiency virus (HIV) epidemic requires re-examination of the penal handling of drug misusers. Treating more patients earlier may contribute significantly to prevention strategies, and methods for harm reduction deserve attention. Compulsory treatment or testing of HIV infection is not favoured. The importance of professional training and of research is stressed. Although the immediate focus is on one particular country's policy needs, the issues raised are of wider relevance.
Keywords: Acquired Immunodeficiency Syndrome/ETIOLOGY/*PREVENTION & CONTROL Human Policy Making Public Health Substance Abuse/*COMPLICATIONS JOURNAL ARTICLE

KWDacquiredimmunodeficiencysyndrome/etiology/KWDprevention&controlhumanpolicymakingpublichealthsubstanceabuse/KWDcomplicationsjournalarticle
880830
M8880521

Copyright © 1988 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1988. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1988. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .